{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:18:03Z","timestamp":1768583883063,"version":"3.49.0"},"reference-count":51,"publisher":"Bentham Science Publishers Ltd.","issue":"7","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDD"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alopecia is globally known as a distressing medical disorder that affects\nmen and women, and current commercially available minoxidil solutions are formulated with irritant\nvehicles with frequent complaints of dermatologic adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>This study aimed to investigate further the compatibility of ready-to-use vehicles for the\npreparation of tailored formulations for alopecia treatment, namely TrichoSol\u2122 (a ready-to-use vehicle\nfor personalized hair solutions) and TrichoFoam\u2122 (a ready-to-use vehicle for personalized\nfoam formulations), in combination with minoxidil and other active pharmaceutical ingredients\n(APIs), to establish adequate beyond-use dates (BUD) for the given formulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Products under evaluation were compounded using TrichoSol\u2122 or TrichoFoam\u2122, with\ndirect incorporation of the APIs into these vehicles. Samples were then stored at controlled room\ntemperature for up to 180 days. High-performance liquid chromatography (HPLC) methods were\ndeveloped and validated, and then utilized to evaluate the compatibility of the APIs in TrichoSol\u2122\nand TrichoFoam\u2122. Forced degradation studies were conducted to assess API stability under various\nstress conditions, and Antimicrobial Effectiveness Testing (AET) was performed at 0 and 180 days\nafter compounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>According to our results, BUDs of up to 90-180 days were obtained for the examined formulations\nstored at room temperature, considering a degradation of maximum 10% of the nominal\nconcentration of the APIs within them. The formulations exhibited no discernible physical alterations\nthroughout this period and maintained chemical stability within acceptable limits. Microbiological\nevaluations confirmed the efficacy of the preservative system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Products compounded with TrichoSol\u2122 and TrichoFoam\u2122 showed suitable stability to\nbe used as personalized treatments for alopecia. We can then suggest that the vehicles TrichoSol\u2122\nand TrichoFoam\u2122 present effective solutions for compounding personalized hair care treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0115672018327249241217163930","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:46:12Z","timestamp":1737593172000},"page":"983-997","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the Physicochemical Compatibility of Minoxidil in Combination with Different Active Pharmaceutical Ingredients in Ready-to-use Vehicles for Alopecia Treatment"],"prefix":"10.2174","volume":"22","author":[{"given":"Bruna","family":"Marianni","sequence":"first","affiliation":[{"name":"Global R&amp;D Management, Fagron BV - Fascinatio Boulevard 350, 3065 - WB Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savvas","family":"Koulouridas","sequence":"additional","affiliation":[{"name":"Global R&amp;D Management, Fagron BV - Fascinatio Boulevard 350, 3065 - WB Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-3660","authenticated-orcid":true,"given":"Hudson Caetano","family":"Polonini","sequence":"additional","affiliation":[{"name":"Global R&amp;D Management, Fagron BV - Fascinatio Boulevard 350, 3065 - WB Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.mcna.2021.04.002","volume":"105","author":"Jamerson T.A.","year":"2021","unstructured":"Jamerson T.A.; Aguh C.; An approach to patients with alopecia. Med Clin North Am  2021,105(4),599-610","journal-title":"Med Clin North Am"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/bmj.331.7522.951","volume":"331","author":"Hunt N.","year":"2005","unstructured":"Hunt N.; McHale S.; The psychological impact of alopecia. BMJ  2005,331(7522),951-953","journal-title":"BMJ"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"5140620","DOI":"10.1155\/2023\/5140620","volume":"2023","author":"Yu L.","year":"2023","unstructured":"Yu L.; Moorthy S.; Peng L.; Shen L.; Han Y.; Zhang Z.; Li Y.; Huang X.; Evaluation of anxiety and depression in patients with androgenetic alopecia in Shanghai: A cross\u2010sectional study. Dermatol Ther  2023,2023(1),5140620","journal-title":"Dermatol Ther"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jad.2024.01.152","volume":"350","author":"Yu N.","year":"2024","unstructured":"Yu N.; Guo Y.; Association between alopecia areata, anxiety, and depression: Insights from a bidirectional two-sample Mendelian randomization study. J Affect Disord  2024,350,328-331","journal-title":"J Affect Disord"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/CCID.S10182","volume":"4","author":"Gordon K.","year":"2011","unstructured":"Gordon K.; Gordon K.; Tosti A.; Alopecia: Evaluation and treatment. Clin Cosmet Investig Dermatol  2011,4,101-106","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-017-1280-y","volume":"57","author":"Lolli F.","year":"2017","unstructured":"Lolli F.; Pallotti F.; Rossi A.; Fortuna M.C.; Caro G.; Lenzi A.; Sansone A.; Lombardo F.; Androgenetic alopecia: A review. Endocrine  2017,57(1),9-17","journal-title":"Endocrine"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.det.2013.12.003","volume":"32","author":"Mirmirani P.","year":"2014","unstructured":"Mirmirani P.; Khumalo N.P.; Traction alopecia. Dermatol Clin  2014,32(2),153-161","journal-title":"Dermatol Clin"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"Pratt C.H.","year":"2017","unstructured":"Pratt C.H.; King L.E.; Messenger A.G.; Christiano A.M.; Sundberg J.P.; Alopecia areata. Nat Rev Dis Primers  2017,3(1),17011","journal-title":"Nat Rev Dis Primers"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.52711\/2231-5691.2023.00025","volume":"13","author":"Rahangdale P.C.","year":"2023","unstructured":"Rahangdale P.C.; Wankhade A.M.; A review on-types and treatment of alopecia. Asian J Pharm Res  2023,13(2),123-128","journal-title":"Asian J Pharm Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00403-024-02850-3","volume":"316","author":"Konisky H.","year":"2024","unstructured":"Konisky H.; Balazic E.; Kobets K.; Characterization of alopecia clinical trials: An analysis of trials registered on clinicaltrials.gov. Arch Dermatol Res  2024,316(4),116","journal-title":"Arch Dermatol Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1111\/jocd.14537","volume":"20","author":"Nestor M.S.","year":"2021","unstructured":"Nestor M.S.; Ablon G.; Gade A.; Han H.; Fischer D.L.; Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol  2021,20(12),3759-3781","journal-title":"J Cosmet Dermatol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"e12686","DOI":"10.1111\/dth.12686","volume":"31","author":"Goren A.","year":"2018","unstructured":"Goren A.; Naccarato T.; Minoxidil in the treatment of androgenetic alopecia. Dermatol Ther  2018,31(5),e12686","journal-title":"Dermatol Ther"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.15406\/jdc.2021.05.00190","volume":"5","author":"Rambwawasvika H.","year":"2021","unstructured":"Rambwawasvika H.; Alopecia types, current and future treatment. J Cosmet Dermatol  2021,5(4),93-99","journal-title":"J Cosmet Dermatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2147\/DDDT.S427612","volume":"17","author":"Shen Y.","year":"2023","unstructured":"Shen Y.; Zhu Y.; Zhang L.; Sun J.; Xie B.; Zhang H.; Song X.; New target for Minoxidil in the treatment of androgenetic alopecia. Drug Des Devel Ther  2023,17,2537-2547","journal-title":"Drug Des Devel Ther"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jaad.2024.05.037","volume":"91","author":"Raval R.S.","year":"2024","unstructured":"Raval R.S.; Nohria A.; Desai D.; Mourtzanakis K.; Buontempo M.; Shapiro J.; Lo Sicco K.; The use of minoxidil in the treatment of alopecia areata: A systematic review. J Am Acad Dermatol  2024,91(3),508-509","journal-title":"J Am Acad Dermatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s40257-018-0409-y","volume":"20","author":"Stoehr J.R.","year":"2019","unstructured":"Stoehr J.R.; Choi J.N.; Colavincenzo M.; Vanderweil S.; Off-label use of topical minoxidil in alopecia: A review. Am J Clin Dermatol  2019,20(2),237-250","journal-title":"Am J Clin Dermatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.2147\/DDDT.S214907","volume":"13","author":"Suchonwanit P.","year":"2019","unstructured":"Suchonwanit P.; Thammarucha S.; Leerunyakul K.; Minoxidil and its use in hair disorders: A review. Drug Des Devel Ther  2019,13,2777-2786","journal-title":"Drug Des Devel Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1067\/mjd.2002.119104","volume":"46","author":"Friedman E.S.","year":"2002","unstructured":"Friedman E.S.; Friedman P.M.; Cohen D.E.; Washenik K.; Allergic contact dermatitis to topical minoxidil solution: Etiology and treatment. J Am Acad Dermatol  2002,46(2),309-312","journal-title":"J Am Acad Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.6084\/m9.figshare.12029772","volume":"10","author":"Suneel R.S.","year":"2020","unstructured":"Suneel R.S.; Shivani V.; Nikhil Kumar A.; Amey K.; Suyog M.; Sujeet M.; Charugulla N.; Comparative study to evaluate tolerability of topical 5% Minoxidil novel formulation and alcohol-based conventional solutions in treatment of androgenetic alopecia in Indian men: Randomized double-blind Study. Dermatol Ther (Heidelb)  2020,10,469-479","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4236\/jcdsa.2017.71001","volume":"07","author":"Amaral F.","year":"2017","unstructured":"Amaral F.; Jardim M.; de Souza Antunes V.M.; Michelin L.F.G.; dos Santos B.A.R.; Barbosa C.M.V.; Spindola D.G.; Bincoletto C.; Oliveira C.R.; EEffects of the phytocomplex TrichoTechTM on human fibroblasts: Proliferative potential and effects on gene expression of FGF-7 and FGF-10. J Cosmet Dermatol Sci Applic  2017,07,1-13","journal-title":"J Cosmet Dermatol Sci Applic"},{"key":"ref=21","first-page":"440","volume":"28","author":"Polonini H.C.","year":"2024","unstructured":"Polonini H.C.; Taylor S.; Silva C.C.V.; Compatibility of cetirizine hydrochloride, dutasteride, hydrocortisone acetate, nicotinamide, progesterone, and pyridoxine hydrochloride in TrichoSolTM, A natural vehicle for hair solutions. Int J Pharm Compd  2024,28,440-447","journal-title":"Int J Pharm Compd"},{"key":"ref=22","first-page":"161","volume":"28","author":"Polonini H.C.","year":"2024","unstructured":"Polonini H.C.; Sousa P.L.; Silva C.C.V.; Compatibility of caffeine clobetasol propionate dutasteride nicotinamide and progesterone in TrichoFoam\u2122, a natural vehicle for hair foams. Int J Pharm Compd  2024,28(2),161-168","journal-title":"Int J Pharm Compd"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/scipharm90010016","volume":"90","author":"Polonini H.","year":"2022","unstructured":"Polonini H.; Taylor S.; Zander C.; Compatibility of different formulations in TrichoConceptTM vehicles for hair treatments. Sci Pharm  2022,90(1),16","journal-title":"Sci Pharm"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/scipharm91030039","volume":"91","author":"Polonini H.C.","year":"2023","unstructured":"Polonini H.C.; Silva C.C.V.; Compounded hair solutions and foams containing Minoxidil: Does the color change impact stability? Sci Pharm  2023,91(3),39","journal-title":"Sci Pharm"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1055\/a-2196-4713","volume":"40","author":"Panchaprateep R.","year":"2024","unstructured":"Panchaprateep R.; Medical treatment for androgenetic alopecia. Facial Plast Surg  2024,40(2),252-266","journal-title":"Facial Plast Surg"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5021\/ad.2012.24.3.295","volume":"24","author":"Kim J.H.","year":"2012","unstructured":"Kim J.H.; Lee S.Y.; Lee H.J.; Yoon N.Y.; Lee W.S.; The efficacy and safety of 17\u03b1-Estradiol (Ell-Cranell\u00ae alpha 0.025%) solution on female pattern hair loss: Single center, open-label, non-comparative, phase iv study. Ann Dermatol  2012,24(3),295-305","journal-title":"Ann Dermatol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13555-020-00379-7","volume":"10","author":"Molinelli E.","year":"2020","unstructured":"Molinelli E.; Campanati A.; Brisigotti V.; Sapigni C.; Paolinelli M.; Offidani A.; Efficacy and safety of topical calcipotriol 0.005% versus topical clobetasol 0.05% in the management of alopecia areata: An intrasubject pilot study. Dermatol Ther (Heidelb)  2020,10(3),515-521","journal-title":"Dermatol Ther (Heidelb)"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/jdv.17738","volume":"36","author":"Piraccini B.M.","year":"2022","unstructured":"Piraccini B.M.; Blume-Peytavi U.; Scarci F.; Jansat J.M.; Falqu\u00e9s M.; Otero R.; Tamarit M.L.; Galv\u00e1n J.; Tebbs V.; Massana E.; Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: A phase III, randomized, controlled clinical trial. J Eur Acad Dermatol Venereol  2022,36(2),286-294","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jaad.2020.09.093","volume":"84","author":"Pindado-Ortega C.","year":"2021","unstructured":"Pindado-Ortega C.; Saceda-Corralo D.; Moreno-Arrones \u00d3.M.; Rodrigues-Barata A.R.; Hermosa-Gelbard \u00c1.; Ja\u00e9n-Olasolo P.; Va\u00f1\u00f3-Galv\u00e1n S.; Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice. J Am Acad Dermatol  2021,84(5),1285-1294","journal-title":"J Am Acad Dermatol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1159\/000541395","volume":"240","author":"Ding Y.","year":"2024","unstructured":"Ding Y.; Wang C.; Bi L.; Du Y.; Lu C.; Zhao M.; Fan W.; Dutasteride for the treatment of androgenetic alopecia: An updated review. Dermatology  2024,240(5-6),833-843","journal-title":"Dermatology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5603\/fd.101208","volume":"10","author":"Koralewicz M.M.","year":"2024","unstructured":"Koralewicz M.M.; Szatkowska O.A.; Topical solutions for androgenetic alopecia: Evaluating efficacy and safety. Forum Dermatologicum  2024,10(3),71-78","journal-title":"Forum Dermatologicum"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"e13202","DOI":"10.1111\/dth.13202","volume":"33","author":"Fields J.R.","year":"2020","unstructured":"Fields J.R.; Vonu P.M.; Monir R.L.; Schoch J.J.; Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. Dermatol Ther  2020,33(1),e13202","journal-title":"Dermatol Ther"},{"key":"ref=33","year":"2024","unstructured":"U.S. Pharmacopeial Convention. Pharmaceutical compounding - Nonsterile preparations. In United States Pharmacopeia.  Available from:  https:\/\/www.uspnf.com\/sites\/default\/files\/usp_pdf\/EN\/USPNF\/revisions\/gc-795-rb-notice-20200424.pdf2024"},{"key":"ref=34","unstructured":"Drugs Com Available from:  https:\/\/www.drugs.com\/ (accessed on 13 July 2023)."},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3163\/1536-5050.100.1.018","volume":"100","author":"Sweetman S.C.","year":"2012","unstructured":"Sweetman S.C.; Martindale: The complete drug reference. J Med Libr Assoc  2012,100,75-76","journal-title":"J Med Libr Assoc"},{"key":"ref=36","year":"2024","unstructured":"ICH Q1A (R2) stability testing of new drug substances and drug products: Scientific guideline.  Available from:  https:\/\/database.ich.org\/sites\/default\/files\/Q1A%28R2%29%20Guideline.pdf2024"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/cosmetics9050092","volume":"9","author":"Polonini H.","year":"2022","unstructured":"Polonini H.; Marianni B.; Taylor S.; Zander C.; Compatibility of personalized formulations in Cleoderm\u2122, A skin rebalancing cream base for oily and sensitive skin. Cosmetics  2022,9(5),92","journal-title":"Cosmetics"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/B978-0-12-386454-3.00861-7","author":"Guy R.C.","year":"2014","unstructured":"Guy R.C.; International conference on harmonisation Encyclopedia of Toxicology  2014,1070-1070","journal-title":"Encyclopedia of Toxicology"},{"key":"ref=39","year":"2005","unstructured":"Validation of analytical procedures: Text and methodology Q2(R1)  Available from:  https:\/\/database.ich.org\/sites\/default\/files\/Q2%28R1%29%20Guideline.pdf2005"},{"key":"ref=40","unstructured":"Validation of microbial recovery from pharmacopeial articles. United States Pharmacopeia  Available from:  https:\/\/doi.usp.org\/USPNF\/USPNF_M99947_03_01.html"},{"key":"ref=41","year":"2024","unstructured":"Antimicrobial effectiveness testing. In USPNF.  Available from:  https:\/\/doi.usp.org\/USPNF\/USPNF_M98790_03_01.html2024"},{"key":"ref=42","unstructured":"ICH Q1D Bracketing and matrixing designs for stability testing of drug substances and drug products: Scientific guideline. European Medicines Agency"},{"key":"ref=43","first-page":"165","volume":"17","author":"Geiger C.M.","year":"2013","unstructured":"Geiger C.M.; Sorenson B.; Whaley P.A.; Stability of minoxidil in Espumil foam base. Int J Pharm Compd  2013,17(2),165-167","journal-title":"Int J Pharm Compd"},{"key":"ref=44","first-page":"236","volume":"25","author":"Lupatini R.","year":"2021","unstructured":"Lupatini R.; Sidhu R.; Patel H.; Bichar K.; Stability evaluation of minoxidil in FOAMIL foam base with bracketing study design. Int J Pharm Compd  2021,25(3),236-240","journal-title":"Int J Pharm Compd"},{"key":"ref=45","first-page":"256","volume":"27","author":"Spennacchio A.","year":"2023","unstructured":"Spennacchio A.; Lopedota A.A.; Lopalco A.; Dibenedetto M.T.; la Forgia F.M.; Fontana S.; Franco M.; Denora N.; Extemporaneous topical Minoxidil solutions for the treatment of alopecia: Stability studies and incorporation tests of active ingredients in ALOPLUS FAST base. Int J Pharm Compd  2023,27(3),256-262","journal-title":"Int J Pharm Compd"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2310\/7750.2008.08013","volume":"13","author":"Pappas L.","year":"2009","unstructured":"Pappas L.; Kiss A.; Levitt J.; Compatibility of tacrolimus ointment with corticosteroid ointments of varying potencies. J Cutan Med Surg  2009,13(3),140-145","journal-title":"J Cutan Med Surg"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3797\/scipharm.1210-02","volume":"81","author":"Ali M.S.","year":"2013","unstructured":"Ali M.S.; Alam M.S.; Alam N.; Anwer T.; Safhi M.M.; Accelerated stability testing of a clobetasol propionate loaded nanoemulsion as per ICH guideline. Sci Pharm  2013,81(4),1089-1100","journal-title":"Sci Pharm"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/10837450701481181","volume":"12","author":"Kumar R.","year":"2007","unstructured":"Kumar R.; Singh B.; Bakshi G.; Katare O.P.; Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol  2007,12(6),591-601","journal-title":"Pharm Dev Technol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"119709","DOI":"10.1016\/j.ijpharm.2020.119709","volume":"587","author":"Afiune L.A.F.","year":"2020","unstructured":"Afiune L.A.F.; Ushirobira C.Y.; Barbosa D.P.P.; de Souza P.E.N.; Leles M.I.G.; Cunha-Filho M.; Gelfuso G.M.; Soler M.A.G.; Gratieri T.; Novel iron oxide nanocarriers loading finasteride or dutasteride: Enhanced skin penetration for topical treatment of alopecia. Int J Pharm  2020,587,119709","journal-title":"Int J Pharm"},{"key":"ref=50","first-page":"1125","volume":"13","author":"Ali M.S.","year":"2014","unstructured":"Ali M.S.; Alam M.S.; Alam N.; Siddiqui M.R.; Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. Iran J Pharm Res  2014,13(4),1125-1140","journal-title":"Iran J Pharm Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(99)00279-3","volume":"198","author":"Skiba M.","year":"2000","unstructured":"Skiba M.; Skiba-Lahiani M.; Marchais H.; Duclos R.; Arnaud P.; Stability assessment of ketoconazole in aqueous formulations. Int J Pharm  2000,198(1),1-6","journal-title":"Int J Pharm"}],"container-title":["Current Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018327249241217163930","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238743\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115672018327249241217163930","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T05:26:20Z","timestamp":1768541180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238743\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115672018327249241217163930","relation":{},"ISSN":["1567-2018"],"issn-type":[{"value":"1567-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}